Upon ligand binding, GLP-1R activation enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite, collectively improving glycemic control and promoting clinically meaningful weight reduction [19]
Another trial found that semaglutide users experienced better HbA1c control and reduced risk of cardiovascular disease
Other options may be a better fit if: You prefer FDA-approved finished products
In the SURPASS-4 trial, adults with T2DM at heightened cardiovascular risk, who were inadequately managed with oral glucose-lowering agents, once-weekly tirzepatide (5 mg, 10 mg, or 15 mg) were compared to insulin glargine (100 U/mL)
Eli Lilly did run a study to find out what happens when people switch from an injectable GLP-1 drug to Foundayo and found that it helped people maintain most of their weight loss